Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Individualized dlPFC-NAcc Modulation for Anhedonia in adMDD

NCT: NCT05544071 · COMPLETED

NCT IDNCT05544071
StatusCOMPLETED
Start Date2023-02-12
Completion2024-07-31
SponsorXijing Hospital (OTHER)
First posted
Last updated

Brief Summary

This study evaluates a schedule of precise repetitive transcranial magnetic stimulation for depressive adolescent with anhedonia. In this randomized controlled trial, half of the participants will receive repetitive transcranial magnetic stimulation, and the other will receive sham stimulation.

Frequently Asked Questions

What is Individualized dlPFC-NAcc Modulation for Anhedonia in adMDD?

Individualized dlPFC-NAcc Modulation for Anhedonia in adMDD is a clinical trial registered under NCT05544071. Current status: COMPLETED.

What is the status of NCT05544071?

The current status of NCT05544071 (Individualized dlPFC-NAcc Modulation for Anhedonia in adMDD) is: COMPLETED.

When did Individualized dlPFC-NAcc Modulation for Anhedonia in adMDD start?

Individualized dlPFC-NAcc Modulation for Anhedonia in adMDD started on 2023-02-12.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑